Equistone's Concept Life Sciences bolts on Aquila Biomedical

Oscar Geen
30 October 2017

Tweet
Facebook
LinkedIn
Google plus
Send to

Equistone-backed laboratory and consultancy group Concept Life Sciences has acquired pre-clinical contract research organisation Aquila Biomedical.

The acquisition is expected to bolster Concept's discovery capabilities with the addition of Aquila's translational biology offering.

It marks the third bolt-on for the company, which was formed in 2014 through a merger of three Equistone portfolio companies, Peakdale Molecular, Resource & Environment Consultants and Scientific Analysis Laboratories.

The first add-on was laboratory consultants CXR Biosciences in August 2015, followed by pharmaceutical testing business Agenda1 in October 2015.

After the acquisition of Aquila, Concept will employ more than 500 people and is targeting revenues of more than $60m for 2017.

Company
Aquila was founded in 2011 by researchers from the University of Edinburgh. It is a pre-clinical contract research organisation with expertise in immune oncology, immunology and multiplex histology.

People
Equistone Partners Europe – Andi Tomkinson (investment director).
Concept Life Sciences – Michael Fort (chair).
Aquila Biomedical – Stephen Anderton (co-founder).